CurrentCignaPolicy 0270

Tilt Table Testing

Customize your policy alerts

Sign up for Cigna Policy 0270 alerts

Get alerted when Policy 0270 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

This Coverage Policy governs coverage of tilt table testing used for the diagnosis and evaluation of select individuals with syncope. It applies to health benefit plans administered by Cigna Companies, subject to the applicable benefit plan document and laws or mandates.

Policy Summary

PayerCigna

PolicyTilt Table Testing

Policy CodePolicy 0270

Change TypeAnnual review — no material clinical or coverage changes

Effective DateNov 15, 20261d

Next Review DateNov 15, 2027

Key ActionFor unexplained syncope, document a complete history and physical examination and appropriate diagnostic testing, including a 12-lead ECG, echocardiogram, and formal exercise tolerance testing, before tilt table testing is considered medically necessary.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Medically necessary syncope indications

9Explicitly noncovered indications

93660Covered tilt table testing CPT code

R55Covered syncope and collapse diagnosis code

OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

CurrentCignaPolicy 0270

Tilt Table Testing

Customize your policy alerts

Sign up for Cigna Policy 0270 alerts

Get alerted when Policy 0270 changes without checking for updates manually.

Monitor payer policy activity

Receive email alerts as soon as relevant payer policies are published or updated.

Policy Summary

PayerCigna

PolicyTilt Table Testing

Policy CodePolicy 0270

Change TypeAnnual review — no material clinical or coverage changes

Effective DateNov 15, 20261d

Next Review DateNov 15, 2027

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

3Medically necessary syncope indications

9Explicitly noncovered indications

93660Covered tilt table testing CPT code

R55Covered syncope and collapse diagnosis code

Primary clinical condition addressed

Medical Necessity and Noncovered Indications

Medically Necessary Indications

Tilt table testing with or without the administration of provocative agents (e.g., isoproterenol) is considered medically necessary when ANY of the following indications apply:

ANY of the following

The individual has syncope, with or without structural heart disease, and the cause of syncope has not been established following a complete history and physical examination and appropriate diagnostic testing, including a twelve-lead electrocardiogram (ECG), echocardiogram, and formal exercise tolerance testing.
The suspected cause of syncope, such as asystole or high-degree atrioventricular (AV) block, has already been established, but tilt table testing results are needed to determine the treatment plan.
Tilt table testing is needed to differentiate convulsive syncope from epilepsy.

Not Covered Indications

Tilt table testing is not covered or reimbursable when performed for ANY other indication.

ANY of the following

Any indication other than the medically necessary indications specified above.
A single syncopal episode when clinical features support a diagnosis of vasovagal syncope.
Syncope in which a specific alternate cause has been established and demonstration of neurally mediated syncope would not alter the treatment plan.
Evaluation of an individual with unexplained recurrent falls without a history of symptoms associated with vasovagal syncope.
Recurrent near syncope or dizziness presumed to be neurally mediated in origin.
Evaluation of unexplained syncope when neuropathies or dysautonomias may contribute to symptomatic hypotension.

Tilt table testing is not covered or reimbursable for a single syncopal episode when clinical features support a diagnosis of vasovagal syncope.

Tilt table testing is not covered or reimbursable for syncope in which a specific alternate cause has been established and in which the potential demonstration of neurally mediated syncope would not alter the treatment plan.

Tilt table testing is not covered or reimbursable for evaluation of an individual with unexplained recurrent falls without a history of symptoms associated with vasovagal syncope.

Tilt table testing is not covered or reimbursable for recurrent near syncope or dizziness presumed to be neurally mediated in origin.

Tilt table testing is not covered or reimbursable for evaluation of unexplained syncope when neuropathies or dysautonomias may contribute to symptomatic hypotension.

Tilt table testing is not covered or reimbursable for follow-up evaluation of therapy intended to prevent syncope recurrences.

Tilt table testing is not covered or reimbursable for chronic fatigue syndrome, recurrent vertigo, or recurrent transient ischemic attacks.

Covered Codes and Clinical Coding Parameters

Considered Medically Necessary CPT CodeCPTCovered

93660

Evaluation of cardiovascular function with tilt table evaluation, with continuous ECG monitoring and intermittent blood pressure monitoring, with or without pharmacological intervention

Considered Medically Necessary ICD-10-CM Diagnosis CodeICD-10Covered

R55	Syncope and collapse

Not Covered or ReimbursableICD-10Not Covered

All other codes

All other ICD-10-CM diagnosis codes

Tilt Table Testing Parameters

Tilt angle60-90°

Starting positionSupine position for 20-45 minutes before testing

MonitoringAt least three ECG leads record simultaneously, with continuous blood pressure readings

POTS Diagnostic Threshold in Adults

Adult diagnostic increase>30 beats per minute

TimingWithin 10 minutes of standing upright

Documentation, Billing, and Utilization Guidance

Documentation Required

Document the Initial Syncope Evaluation

Document a complete history and physical examination and appropriate diagnostic testing before requesting tilt table testing for syncope. The initial evaluation must include a 12-lead ECG, echocardiogram, and formal exercise tolerance testing, and the cause of syncope must remain unestablished after that evaluation.

Applies to individuals with or without structural heart disease.
Tilt table testing may be performed with or without provocative agents such as isoproterenol.

Documentation Required

Support the Treatment-Planning Rationale

When the suspected cause of syncope has already been established, document the suspected cause and explain why tilt table test results are needed to determine the treatment plan. Examples include asystole or high-degree atrioventricular (AV) block.

Link the requested test results to a specific treatment-planning decision.
Testing is medically necessary only when the results will contribute to establishing appropriate treatment.

Policy Scope and Clinical Context

This Coverage Policy addresses tilt table testing with or without provocative agents for the diagnosis and evaluation of select individuals with syncope. The policy is a coverage document, not a treatment guideline, and does not constitute a recommendation for treatment.

Key Clinical Definitions

Syncope

DefinitionA transient loss of consciousness triggered by a period of inadequate oxygen delivery to the brain

Most frequent causeSystemic hypotension

Other termsAlso called fainting or passing out

Tilt Table Testing

DefinitionA test using a tilting table with a footboard in which an individual rests supine and is then moved to an upright position

PositioningThe table rapidly moves to an upright position of 60-90° after 20-45 minutes in the supine position

Monitored parameters

Policy Summary

PayerCigna

PolicyTilt Table Testing

Policy CodePolicy 0270

Change TypeAnnual review — no material clinical or coverage changes

Effective DateNov 15, 20261d

Next Review DateNov 15, 2027

SourceLink

On This Page

Follow-up evaluation of therapy intended to prevent syncope recurrences.

Chronic fatigue syndrome.

Recurrent transient ischemic attacks.

Additional characteristic

Occurs in the absence of orthostatic hypotension

POTS Diagnostic Threshold in Individuals Aged 12-19 Years

Applicable age rangeIndividuals aged 12-19 years

Diagnostic heart-rate increase≥40 beats per minute

TimingWithin 10 minutes of assuming an upright posture

Documentation Required

Differentiate Convulsive Syncope from Epilepsy

When distinguishing convulsive syncope from epilepsy, document the clinical features that make the distinction necessary and provide the diagnostic rationale for tilt table testing. The test is reasonable in selected patients when the diagnosis remains uncertain after the initial evaluation.

Explain why convulsive movements or other features cannot be adequately classified by the initial evaluation alone.
Use the results to support differentiation of convulsive syncope from epilepsy.

Billing Rule

Submit Covered Codes and Diagnoses

Submit the covered diagnosis and procedure codes that accurately represent the service and the patient's covered syncope indication. Reimbursement is not allowed when services are billed for conditions or diagnoses that are not covered under this policy; claims without covered codes may be denied as not covered.

Use the most appropriate codes in effect on the date of submission.
Review the applicable benefit plan document and submit covered code(s) and diagnosis(es) consistent with the policy criteria.

Denial Risk

Do Not Use for Noncovered Indications

Do not request or bill tilt table testing for indications outside the medically necessary syncope criteria. Testing is not covered or reimbursable for the following indications.

A single syncopal episode when clinical features support vasovagal syncope.
Syncope with an established alternate cause when demonstrating neurally mediated syncope would not alter treatment.
Unexplained recurrent falls without symptoms associated with vasovagal syncope.
Recurrent near syncope or dizziness presumed to be neurally mediated.
Unexplained syncope when neuropathies or dysautonomias may contribute to symptomatic hypotension.
Follow-up evaluation of therapy to prevent syncope recurrences.
Chronic fatigue syndrome, recurrent vertigo, or recurrent transient ischemic attacks.

Denial Risk

Do Not Use for Treatment Monitoring or Athlete Testing

Do not use tilt table testing to monitor response to syncope treatment or to evaluate athletes with syncope. Published evidence and professional guidance do not establish value for treatment monitoring, and athlete testing has limited diagnostic utility because physiologic adaptations increase false-positive results and may lead to inappropriate interventions.

ACC/AHA/HRS guidelines do not recommend tilt table testing to predict response to medical treatment for vasovagal syncope.
The 2024 HRS expert consensus statement does not recommend tilt table testing in athletes with syncope because of the high prevalence of false positives.
ESC guidance states that tilt testing should not be used to assess the efficacy of drug treatment.
Document another clinically appropriate indication when testing is requested.

Billing Rule

Use Only Listed Covered Diagnosis Codes

Diagnosis codes other than the listed covered syncope diagnosis code are not covered or reimbursable under this policy. Submit only the listed covered diagnosis code when billing tilt table testing; claims submitted with all other diagnosis codes may be denied as not covered.

Verify the diagnosis code against the policy's Coding Information before submission.
An unlisted or otherwise noncovered diagnosis code does not establish coverage for the procedure.

At least three ECG leads and continuous blood pressure readings are recorded during the study

Provocative agentsIntravenous medications such as isoproterenol or nitroglycerin may be used if syncope is not produced by tilt testing alone

Postural Orthostatic Tachycardia Syndrome (POTS)

DefinitionA multisystem disorder of the autonomic nervous system characterized by symptoms of orthostatic intolerance for more than six months

Adult diagnostic characteristicHeart-rate increase of more than 30 beats per minute within 10 minutes of standing upright, without orthostatic hypotension

Adolescent diagnostic characteristicFor individuals aged 12-19 years, the heart-rate increase threshold is at least 40 beats per minute

ExclusionsThe syndrome occurs in the absence of prolonged bed rest, medications that impair autonomic regulation, or other conditions that may cause tachycardia